Therapeutic strategy for SCD-EDS can be achieved through restoring intracellular zinc homeostasis [94], and the removal of mutant ZIP13 protein via the ubiquitin-proteasome pathway [83]. Here, SLC39A13 is linked to Ehlers-Danlos syndrome.